A trial using autologous BMMNCs showed greater clinical improvements in patients with Buerger’s disease in comparison with those with atherosclerotic PAD, and this was associated with greater EPC migration in response to VEGF in Buerger’s disease patients [33]. This evidence concerns the gene VEGFA and thromboangiitis obliterans.